Welcome to our dedicated page for Rapid Dose Thera news (Ticker: RDTCF), a resource for investors and traders seeking the latest updates and insights on Rapid Dose Thera stock.
Rapid Dose Therapeutics Corp. (RDTCF / CSE: DOSE) is a Canadian biotechnology and life sciences company centered on its QuickStrip™ oral thin-film drug delivery platform. The news flow around the company frequently combines product development updates with financing and corporate actions, giving investors insight into both its technology progress and its capital structure.
Readers of this news page can follow announcements on QuickStrip™-based initiatives, including nicotine-focused products such as QuickStrip™ Nicotine and NicStrip™, as well as harm reduction applications like the Replace+ sublingual cannabis strip developed with Eco Canadian Organic Inc. News releases have covered regulatory milestones such as a Health Canada submission for QuickStrip™ Nicotine in multiple dose strengths and details of a pharmacokinetic clinical study comparing nicotine absorption to combustible cigarettes.
In addition to product and partnership updates, Rapid Dose Therapeutics regularly reports on financing-related developments. These include private placement financings involving secured convertible notes and warrants, extensions of note maturities and warrant expiries, and the issuance of common shares to pay accrued interest on secured debt. The company has also disclosed shares-for-debt transactions with creditors and directors aimed at reducing outstanding liabilities.
By reviewing the news items linked on this page, investors and observers can track how Rapid Dose Therapeutics advances its QuickStrip™ technology across nicotine, cannabis, nutraceutical and pharmaceutical applications, while also monitoring share issuances, note terms and other corporate actions that affect its capital structure. This page is a central source for the company’s publicly released updates and disclosures.
Rapid Dose Therapeutics (CSE: DOSE) has announced plans to issue common shares to satisfy the quarterly interest payment due March 31, 2025, on its secured convertible notes. The company will issue 463,716 common shares at $0.20 per share, totaling $92,745.22 in accrued interest.
The notes, issued in 2023 through a private placement financing of $3,134,445, carry a 12% annual interest rate and mature on November 30, 2025. The financing included units priced at $1.00, each comprising notes and five common share purchase warrants, resulting in 15,672,225 warrants issued.
Additionally, RDT has received an extension from the CSE until April 24, 2025, to complete its previously announced shares-for-debt transaction. This transaction involves issuing up to 1,600,000 common shares at $0.25 per share to settle approximately $400,000 in outstanding accounts payable with creditors.
Rapid Dose Therapeutics Corp (CSE: DOSE) has announced plans for an equity private placement financing to raise up to $5,000,000 in gross proceeds. The financing will consist of up to 20,833,333 common shares priced at $0.24 per share.
The company has engaged Meadowbank Asset Management Inc. as the agent, who will receive a 1% cash commission on proceeds from investors they introduce, plus agent warrants equal to 6% of shares issued to their referred investors. Each agent warrant will be exercisable at $0.33 per share for two years.
The proceeds will be used for debt retirement, research and development, capital expansion, and working capital. The financing may close in multiple tranches, with securities subject to a four-month hold period.
Rapid Dose Therapeutics (CSE: DOSE) has expanded its collaboration with an unnamed international company in oral nicotine products through an exclusive pre-commercialization agreement extending to June 19, 2025. The agreement involves RDT providing project management and product development services for a monthly fee of USD$120,000.
The collaboration, which began in December 2022, focuses on finalizing innovative, market-ready products for launch in 2025. Key development areas include formulation optimization, packaging enhancement, consumer studies, product benchmarking, and regulatory documentation preparation. The partnership leverages RDT's proprietary QuickStrip™ Oral Thin Film (OTF) technology to develop next-generation smoke-free alternatives.
Rapid Dose Therapeutics (CSE: DOSE) has received an extension from the Canadian Securities Exchange for its previously announced debt settlement transaction. The extension allows the company to close the Shares for Debt Transaction by March 10, 2025. The transaction involves issuing up to 1,600,000 common shares at $0.25 per share to creditors in exchange for canceling approximately $400,000 in outstanding accounts payable.
Additionally, the company announced it will not proceed with the previously disclosed private placement of units (shares and warrants) worth up to $6,000,000 at this time.
Rapid Dose Therapeutics (CSE: DOSE) has completed a shares for debt transaction with its non-management directors. The company issued 681,815 Debt Shares at $0.22 per share to settle an aggregate debt of $150,000 in directors' fees.
The debt comprised of $10,000 owed to each of the five directors for the fiscal quarters ended May 31, August 31, and November 30, 2024. The share price was set at the closing market price on December 31, 2024. The issued shares are subject to a four-month hold period.
This transaction aims to improve the company's financial position by reducing existing liabilities. The issuance constitutes a related party transaction under MI 61-101, with the company utilizing exemptions from valuation and minority shareholder approval requirements.
Rapid Dose Therapeutics (CSE: DOSE) announced plans to issue common shares to satisfy the quarterly interest payment due December 31, 2024, on its secured convertible notes. The company will issue 430,930 common shares at $0.22 per share to cover $94,806.23 in accrued interest.
This share issuance stems from the company's previous private placement financing, where RDT issued $3,134,445 in principal amount of Notes and 15,672,225 Warrants in 2023. The Notes, maturing on November 30, 2025, carry a 12.0% annual interest rate, payable quarterly in common shares. The share price is determined by the closing market price on the CSE at each quarter's end.
The newly issued shares will be subject to a four-month and one-day hold period from their issue date, expected no later than January 15, 2025.
Rapid Dose Therapeutics (CSE: DOSE) has announced a shares-for-debt transaction with its five non-management directors to settle outstanding director fees. Each director is owed $10,000 for three fiscal quarters (May 31, August 31, and November 30, 2024), totaling an aggregate debt of $150,000.
The company will issue common shares at a price equal to the closing market price on December 31, 2024, with expected issuance around January 15, 2025. The shares will be subject to a four-month hold period. This transaction aims to improve RDT's financial position by reducing existing liabilities. No new control person will be created through this transaction.
Rapid Dose Therapeutics (CSE: DOSE) has announced a proposed equity private placement financing aiming to raise up to $6,000,000 through the issuance of up to 24,000,000 units at $0.25 per unit. Each unit includes one common share and one warrant exercisable at $0.33 for two years.
The company plans to use the proceeds for debt retirement, research and development, capital expansion, and working capital. Meadowbank Asset Management will serve as the agent, receiving a 1% cash commission and 6% in agent warrants.
Additionally, RDT plans to settle up to $400,000 in debt through the issuance of up to 1,600,000 common shares at a minimum price of $0.25 per share to improve its financial position.
Rapid Dose Therapeutics Corp. (CSE: DOSE) has filed a patent application for its Lidocaine Oral Thin Film Strip with the Canadian Intellectual Property Office. The innovative product offers an alternative to traditional dental anesthesia methods, delivering lidocaine through a dissolvable strip that adheres to oral mucosa.
The Lidocaine QuickStrip™ provides precise application, complete dissolution, and efficient absorption. It can be used for various dental applications, including pre-procedure anesthesia and post-operative pain control. The product aims to reduce patient anxiety and save dentists' chair time by eliminating the traditional needle administration process, which typically takes up to five minutes with conventional methods.
Rapid Dose Therapeutics Corp. (CSE: DOSE) has completed the second and final tranche of its equity private placement financing, raising $542,000 through the issuance of 3,188,233 common shares at $0.17 per share. Combined with the first tranche, the company has raised total gross proceeds of $851,000. The financing had a maximum capacity of $6,000,000. Proceeds will support research and development, capital expansion, debt repayment, and working capital needs. The issued shares are subject to a four-month hold period.